Prostate cancer is the second most commonly diagnosed cancer in men globally, with outcomes ranging from indolent low-risk disease managed with active surveillance to lethal castration-resistant metastatic disease. Next-generation androgen receptor pathway inhibitors, PARP inhibitors in HRR-mutated disease, and PSMA-targeted radioligand therapy have substantially expanded the treatment landscape. Liquid biopsy and PSMA-PET imaging are transforming staging and response monitoring.
Loading articles...
